USPTO serial 97690153
SURMOUNT BIO
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- TARABAN, LAURA KRISTEN
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with SURMOUNT BIO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Maury M. Tepper, III
Maury M. Tepper, III TEPPER & EYSTER, PLLC3724 BENSON DRIVERALEIGH, NC 27609United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Gene therapy products, namely, genetically engineered tissues for transplant purposes; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, antivirals; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Anti-cancer preparations; Biological preparations for the treatment of cancer; Digestives for pharmaceutical purposes; Drug delivery agents in the form of a capsule, pill, or liquid that facilitate the delivery of pharmaceutical preparations; Medical preparations for the treatment of cancer, cystic fibrosis, heart disease, and AIDS; Medicinal infusions for treating Cancer, cystic fibrosis, heart disease, and AIDS; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Mixed biological preparations for the prevention and treatment of infectious diseases; Pharmaceutical preparations for the treatment and prevention of Cancer, cystic fibrosis, heart disease, and AIDS; Pharmaceutical products for the prevention and treatment of cancer; Radioactive pharmaceutical preparations for use in vivo diagnostic or therapeutic use; Specialized tablets, capsules and powders for the delivery of pharmaceuticals sold without the pharmaceutical ingredient; Therapeutic pharmaceutical for the treatment of Cancer, cystic fibrosis, heart disease, and AIDS; Unit dose capsules sold empty for pharmaceutical use | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 16, 2025 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 16, 2025 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Nov 19, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 19, 2024 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Nov 19, 2024 | EXT2 | SOU EXTENSION 2 FILED | — |
| Nov 19, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 13, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 7, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jun 7, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jun 7, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 12, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 17, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 17, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 27, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 11, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 11, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 11, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 11, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 11, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 16, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 28, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 26, 2022 | NWAP | NEW APPLICATION ENTERED | — |